Roy-Vallejo, EmiliaSánchez Purificación, AquilinoTorres Peña, José DavidSánchez Moreno, BeatrizArnalich, FranciscoGarcía Blanco, María JoséLópez Miranda, JoséRomero-Cabrera, Juan LuisHerrero Gil, Carmen RosarioBascunana, JoséRubio-Rivas, ManuelPintos Otero, SaraMartínez Sempere, VerónicaBallano Rodríguez-Solís, JesúsGil Sánchez, RicardoLuque Del Pino, JairoGonzález Noya, AmaraNavas-Alcántara, María SierraCortés Rodríguez, BegoñaAlcalá, José NicolásSuárez-Lombraña, AnaAndrés Soler, JorgeGómez-Huelgas, RicardoCasas-Rojo, José ManuelMillán Núñez-Cortés, JesúsOn Behalf Of The Semi-Covid-Network,2024-02-192024-02-192021-06-152077-0383http://hdl.handle.net/10668/18098http://hdl.handle.net/20.500.12105/18379Our main aim was to describe the effect on the severity of ACEI (angiotensin-converting enzyme inhibitor) and ARB (angiotensin II receptor blocker) during COVID-19 hospitalization. A retrospective, observational, multicenter study evaluating hospitalized patients with COVID-19 treated with ACEI/ARB. The primary endpoint was the incidence of the composite outcome of prognosis (IMV (invasive mechanical ventilation), NIMV (non-invasive mechanical ventilation), ICU admission (intensive care unit), and/or all-cause mortality). We evaluated both outcomes in patients whose treatment with ACEI/ARB was continued or withdrawn. Between February and June 2020, 11,205 patients were included, mean age 67 years (SD = 16.3) and 43.1% female; 2162 patients received ACEI/ARB treatment. ACEI/ARB treatment showed lower all-cause mortality (pengVoRhttp://creativecommons.org/licenses/by/4.0/ACEIARBCOVID-19MACEprognosisAttribution 4.0 International34204014101210.3390/jcm10122642Journal of clinical medicineopen access